APHON Overview
-umab - ANS-completely humanized moabs
-ximab - ANS-moab mixture of human & mouse antibodies
-zumab - ANS-moab humanized, small part of mouse antibody fused w/ human antibody
"second look" - ANS-more than one biopsies, inspect tumor bed to evaluate the volume of
residual ailment
1st line of defense: protective - ANS-anatomic obstacles. Skin, mucus membranes. Nonspecific
protection
2nd line of protection: inflammatory - ANS-nonspecific immunity. Neutrophils--macrophages
ingest overseas antigens
3D conformal radiation - ANS-high dose to focused tumor whilst keeping tight marigin to deliver
low dose to surrounding tissues. Turning into regular baseline radiation
third line defense: immune - ANS-lymphocytes apprehend histiocompatibility leukocyte antigens
(HLA)
60% - ANS-children w/ most cancers enrolled in clinical trial at time of diagnosis
belly malignancy - ANS-pain, weight reduction, anorexia, diarrhea, constipation, hematuria
aberrant cellular department - ANS-number one feature of cancer cellular. Proto-oncogene
transformation, lack of tumor suppressor gene or immortalization
obtained resistance - ANS-tumor develops resistance after publicity to single drug or blend of
medication. Multidrug resistance gene (mdr)
adjuvant chemo - ANS-given post surgery/radiation for malignancies w/ excessive hazard of
residual disease or undetected metastases
alk - ANS-expanded in youngsters w/ osteosarcomas
alkylating dealers - ANS-purpose faulty replication or inhibit replication of DNA causing mobile
mutation or dying. Most energetic in resting phase (cytoxin, ifos, platinum, topiso I)
,alkylating retailers - ANS-non-unique. Even though most energetic in resting segment. Motive
dna strand breaks
alkylating dealers - nonspecific - ANS-pass-link dna strands causing breakage & unusual base
pairing (intercalation) - cyclophos busulfan, melphalan, carmustine, lomustine, cisplatin,
carboplatin
all-trans retinoic acid (atra) - ANS-tx: aml, aml m3 subtype, apl
boom maturation of promyelocytic blasts and fast decision of coagulopathy r/t tx.
Alpha-fetoprotein - ANS-oncogene related w/ hepatoblastoma or germ cellular tumors
alpha-fetoprotein (afp) - ANS-glycoprotien detected in children w/ number one liver or germ
mobile tumors (hepatoblastoma & gct)
alpha-interferon - ANS-leukocyte-derived. Tx: hairy cell leukemia, cancer, persistent myeloid
leukemia, follicular lymphoma, multiple myeloma, cutaneous t-cell lymphoma
angiogenesis - ANS-growth of recent blood vessels from present vessels. Tumor viability
depends for increase. Vascular endothelial boom factors (vegf) cascade primary component
anthracyclines - ANS-prevent rejoining of cleaved dna strands by way of inhibiting
topoisomerase ii (dna untangling enzyme). Also forms hydroxyl radicals which attack dna/cell
membrane lipids (cardiotoxic)
supply cardioprotective sellers along
abx are subset however breakdown is generally solid
antiangiogenic sellers - ANS-pvt increase of recent blood vessels tumors rely on for growth and
metastases by way of:
inhibit endothelial cells, interrupt messaging manner, save you breakdown of matrix tissue and
pvt new cells from linking together to form new vessels
antibodies - ANS-proteins produced by means of b-lymphocytes. Part of humoral immunity of
adaptive gadget. Includes immunoglobulins (igG, igA, igM, igE, igD)
antimetabolites - ANS-intervene w/ cell metabolism via inhibiting enzyme production or
generating nonfunctional end product. Interrupts protein synthesis, rna, or dna
antimetabolites - ANS-mimic metabolic elements and inhibit RNA/DNA synthesis
antimetabolites - particular - ANS-interfere w/ nucleic acid synth required for dna rep & inh prtn
synthesis - mtx, 6mp, 6tg, ara-c
effective in divided doses or continuous infusion
, antitumor abx - nonspecific - ANS-inh dna & rna synthesis, repair, recombination interfering w/
nucleic acid synthesis & feature. - doxorubicin, daunorubicin, dactinomycin, mitomycin
antitumor antibiotics - ANS-non-cell cycle particular. Interfere w/ DNA replication and RNA
transcription. Active in all stages
aphon nursing care consists of - ANS-cancer prevention edu, provision of physical care, support
of bereaved circle of relatives in event of toddler's dying, long term follow up for survivors
apoptosis - ANS-programmed cellular demise by using age or damage to cellular. Intracellular
lysosomes burst, inflicting cell degredation, lysis.
Pathological cell death- stim through necrosis or chemo
location below attention curve (auc) - ANS-publicity to drug over time
asparaginase - ANS-depletes circulating molecular nutrients needed via leukemic cells for ptn
synthesis
asparaginase - ANS-misc agent. L/PEG: mobile-cycle non-unique enzyme, covered w/
polyethylene glycol & decreases immunogenicity of enzyme.
Assent - ANS-child's affirmative agreement to take part in medical trial
ast / alt, bilirubin, total prtn, albumin - ANS-degree hepatic characteristic
audiogram or mind stem evoked response - ANS-audiotoxicity w/ cisplatin. Related w/ excessive
frequency listening to loss. Check completed at dx
b cells - ANS-mature into plasma cells & secrete immunoglobulins. Offer humoral immunity
basophils - ANS-launch histamine in extravascular web sites wherein damage has befell
bcl-1 - ANS-oncogene related w/ breast, head, neck cancers
beta-interferon - ANS-fibroblast-derived. Tx MS
bevacizumab (avastin) - ANS-vegf inhibitor. Pvt angiogenesis. Tx in relapse/refractory stable
tumors
bioavailability - ANS-charge/volume of absorption of drug. Can be laid low with surgical
procedure, radiation, chemo, n/v, concomitant capsules affecting gi motility
distribution suffering from weight, frame fats stores, pleural effusions, ascites
biopsy - ANS-high-quality needle aspiration normally done inside the pelvic bone
-umab - ANS-completely humanized moabs
-ximab - ANS-moab mixture of human & mouse antibodies
-zumab - ANS-moab humanized, small part of mouse antibody fused w/ human antibody
"second look" - ANS-more than one biopsies, inspect tumor bed to evaluate the volume of
residual ailment
1st line of defense: protective - ANS-anatomic obstacles. Skin, mucus membranes. Nonspecific
protection
2nd line of protection: inflammatory - ANS-nonspecific immunity. Neutrophils--macrophages
ingest overseas antigens
3D conformal radiation - ANS-high dose to focused tumor whilst keeping tight marigin to deliver
low dose to surrounding tissues. Turning into regular baseline radiation
third line defense: immune - ANS-lymphocytes apprehend histiocompatibility leukocyte antigens
(HLA)
60% - ANS-children w/ most cancers enrolled in clinical trial at time of diagnosis
belly malignancy - ANS-pain, weight reduction, anorexia, diarrhea, constipation, hematuria
aberrant cellular department - ANS-number one feature of cancer cellular. Proto-oncogene
transformation, lack of tumor suppressor gene or immortalization
obtained resistance - ANS-tumor develops resistance after publicity to single drug or blend of
medication. Multidrug resistance gene (mdr)
adjuvant chemo - ANS-given post surgery/radiation for malignancies w/ excessive hazard of
residual disease or undetected metastases
alk - ANS-expanded in youngsters w/ osteosarcomas
alkylating dealers - ANS-purpose faulty replication or inhibit replication of DNA causing mobile
mutation or dying. Most energetic in resting phase (cytoxin, ifos, platinum, topiso I)
,alkylating retailers - ANS-non-unique. Even though most energetic in resting segment. Motive
dna strand breaks
alkylating dealers - nonspecific - ANS-pass-link dna strands causing breakage & unusual base
pairing (intercalation) - cyclophos busulfan, melphalan, carmustine, lomustine, cisplatin,
carboplatin
all-trans retinoic acid (atra) - ANS-tx: aml, aml m3 subtype, apl
boom maturation of promyelocytic blasts and fast decision of coagulopathy r/t tx.
Alpha-fetoprotein - ANS-oncogene related w/ hepatoblastoma or germ cellular tumors
alpha-fetoprotein (afp) - ANS-glycoprotien detected in children w/ number one liver or germ
mobile tumors (hepatoblastoma & gct)
alpha-interferon - ANS-leukocyte-derived. Tx: hairy cell leukemia, cancer, persistent myeloid
leukemia, follicular lymphoma, multiple myeloma, cutaneous t-cell lymphoma
angiogenesis - ANS-growth of recent blood vessels from present vessels. Tumor viability
depends for increase. Vascular endothelial boom factors (vegf) cascade primary component
anthracyclines - ANS-prevent rejoining of cleaved dna strands by way of inhibiting
topoisomerase ii (dna untangling enzyme). Also forms hydroxyl radicals which attack dna/cell
membrane lipids (cardiotoxic)
supply cardioprotective sellers along
abx are subset however breakdown is generally solid
antiangiogenic sellers - ANS-pvt increase of recent blood vessels tumors rely on for growth and
metastases by way of:
inhibit endothelial cells, interrupt messaging manner, save you breakdown of matrix tissue and
pvt new cells from linking together to form new vessels
antibodies - ANS-proteins produced by means of b-lymphocytes. Part of humoral immunity of
adaptive gadget. Includes immunoglobulins (igG, igA, igM, igE, igD)
antimetabolites - ANS-intervene w/ cell metabolism via inhibiting enzyme production or
generating nonfunctional end product. Interrupts protein synthesis, rna, or dna
antimetabolites - ANS-mimic metabolic elements and inhibit RNA/DNA synthesis
antimetabolites - particular - ANS-interfere w/ nucleic acid synth required for dna rep & inh prtn
synthesis - mtx, 6mp, 6tg, ara-c
effective in divided doses or continuous infusion
, antitumor abx - nonspecific - ANS-inh dna & rna synthesis, repair, recombination interfering w/
nucleic acid synthesis & feature. - doxorubicin, daunorubicin, dactinomycin, mitomycin
antitumor antibiotics - ANS-non-cell cycle particular. Interfere w/ DNA replication and RNA
transcription. Active in all stages
aphon nursing care consists of - ANS-cancer prevention edu, provision of physical care, support
of bereaved circle of relatives in event of toddler's dying, long term follow up for survivors
apoptosis - ANS-programmed cellular demise by using age or damage to cellular. Intracellular
lysosomes burst, inflicting cell degredation, lysis.
Pathological cell death- stim through necrosis or chemo
location below attention curve (auc) - ANS-publicity to drug over time
asparaginase - ANS-depletes circulating molecular nutrients needed via leukemic cells for ptn
synthesis
asparaginase - ANS-misc agent. L/PEG: mobile-cycle non-unique enzyme, covered w/
polyethylene glycol & decreases immunogenicity of enzyme.
Assent - ANS-child's affirmative agreement to take part in medical trial
ast / alt, bilirubin, total prtn, albumin - ANS-degree hepatic characteristic
audiogram or mind stem evoked response - ANS-audiotoxicity w/ cisplatin. Related w/ excessive
frequency listening to loss. Check completed at dx
b cells - ANS-mature into plasma cells & secrete immunoglobulins. Offer humoral immunity
basophils - ANS-launch histamine in extravascular web sites wherein damage has befell
bcl-1 - ANS-oncogene related w/ breast, head, neck cancers
beta-interferon - ANS-fibroblast-derived. Tx MS
bevacizumab (avastin) - ANS-vegf inhibitor. Pvt angiogenesis. Tx in relapse/refractory stable
tumors
bioavailability - ANS-charge/volume of absorption of drug. Can be laid low with surgical
procedure, radiation, chemo, n/v, concomitant capsules affecting gi motility
distribution suffering from weight, frame fats stores, pleural effusions, ascites
biopsy - ANS-high-quality needle aspiration normally done inside the pelvic bone
